Barclays PLC Fibrogen Inc Call Options Transaction History

Barclays PLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2021 Aug 13, 2021	BUY	$18.57 - $35.68 $68,709 - $132,016	3,700 Added 308.33%	4,900 $130,000
Q2 2019 Aug 14, 2019	SELL	$35.13 - $55.53 $242,397 - $383,157	-6,900 Reduced 85.19%	1,200 $54,000
Q1 2019 May 15, 2019	BUY	$42.83 - $59.91 $304,093 - $425,361	7,100 Added 710.0%	8,100 $440,000
Q4 2018 Feb 14, 2019	BUY	$37.97 - $60.16 $22,782 - $36,096	600 Added 150.0%	1,000 $46,000
Q3 2018 Nov 14, 2018	SELL	$56.3 - $67.25 $1.5 Million - $1.79 Million	-26,600 Reduced 98.52%	400 $24,000
Q1 2018 May 15, 2018	BUY	$45.35 - $61.65 $1.22 Million - $1.66 Million	27,000 New	27,000 $1.25 Million

46.8M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $53.4M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.